KPIs & Operating Metrics(New)
Growth Metrics

Abbott Laboratories (ABT) Depreciation & Amortization (CF) (2016 - 2026)

Abbott Laboratories' Depreciation & Amortization (CF) history spans 18 years, with the latest figure at $381.0 million for Q1 2026.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 13.39% to $381.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.5 billion, a 10.13% increase, with the full-year FY2025 number at $1.4 billion, up 7.01% from a year prior.
  • Depreciation & Amortization (CF) hit $381.0 million in Q1 2026 for Abbott Laboratories, up from $370.0 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for ABT hit a ceiling of $381.0 million in Q1 2026 and a floor of $302.0 million in Q2 2023.
  • Historically, Depreciation & Amortization (CF) has averaged $334.5 million across 5 years, with a median of $332.0 million in 2023.
  • Biggest five-year swings in Depreciation & Amortization (CF): decreased 26.82% in 2022 and later increased 13.39% in 2026.
  • Tracing ABT's Depreciation & Amortization (CF) over 5 years: stood at $311.0 million in 2022, then rose by 6.75% to $332.0 million in 2023, then grew by 3.01% to $342.0 million in 2024, then rose by 8.19% to $370.0 million in 2025, then increased by 2.97% to $381.0 million in 2026.
  • Business Quant data shows Depreciation & Amortization (CF) for ABT at $381.0 million in Q1 2026, $370.0 million in Q4 2025, and $371.0 million in Q3 2025.